Apolipoprotein B - An ideal biomarker for atherosclerosis?

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Indian heart journal Pub Date : 2024-03-01 DOI:10.1016/j.ihj.2023.12.001

Kavita Singh , Dorairaj Prabhakaran

{"title":"Apolipoprotein B - An ideal biomarker for atherosclerosis?","authors":"Kavita Singh , Dorairaj Prabhakaran","doi":"10.1016/j.ihj.2023.12.001","DOIUrl":null,"url":null,"abstract":"<div><p>This review article describes the pathophysiological mechanisms linking Apolipoprotein B (Apo-B) and atherosclerosis, summarizes the existing evidence on Apo B as a predictor of atherosclerotic cardiovascular disease and recommendations of (inter)national treatment guidelines regarding Apo B in dyslipidemia management. A single Apo B molecule is present in every particle of very low-density lipoprotein, intermediate density lipoprotein, low density lipoprotein, and lipoprotein(a). This unique single Apo B per particle ratio makes plasma Apo B concentration a direct measure of the number of circulating atherogenic lipoproteins. This review of global evidence on Apo B as a biomarker for atherosclerosis confirms that Apo B is a single atherogenic lipid marker present in all lipids sub-fractions except HDL-C, and thus, Apo B integrates and extends the information from triglycerides and cholesterol, which could simplify and improve care for atherosclerotic cardiovascular disease.</p></div>","PeriodicalId":13384,"journal":{"name":"Indian heart journal","volume":"76 ","pages":"Pages S121-S129"},"PeriodicalIF":1.4000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0019483223004704/pdfft?md5=494705d5aeaa65d153a83d958f354624&pid=1-s2.0-S0019483223004704-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian heart journal","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0019483223004704","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

This review article describes the pathophysiological mechanisms linking Apolipoprotein B (Apo-B) and atherosclerosis, summarizes the existing evidence on Apo B as a predictor of atherosclerotic cardiovascular disease and recommendations of (inter)national treatment guidelines regarding Apo B in dyslipidemia management. A single Apo B molecule is present in every particle of very low-density lipoprotein, intermediate density lipoprotein, low density lipoprotein, and lipoprotein(a). This unique single Apo B per particle ratio makes plasma Apo B concentration a direct measure of the number of circulating atherogenic lipoproteins. This review of global evidence on Apo B as a biomarker for atherosclerosis confirms that Apo B is a single atherogenic lipid marker present in all lipids sub-fractions except HDL-C, and thus, Apo B integrates and extends the information from triglycerides and cholesterol, which could simplify and improve care for atherosclerotic cardiovascular disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

载脂蛋白 B--动脉粥样硬化的理想生物标志物？

这篇综述文章描述了载脂蛋白 B（Apo-B）与动脉粥样硬化之间的病理生理机制，总结了载脂蛋白 B 作为动脉粥样硬化性心血管疾病预测因子的现有证据，以及各国（间）治疗指南对血脂异常管理中载脂蛋白 B 的建议。极低密度脂蛋白、中密度脂蛋白、低密度脂蛋白和脂蛋白（a）的每一个颗粒中都有一个载脂蛋白 B 分子。这种独特的每颗粒单一载脂蛋白 B 比率使血浆载脂蛋白 B 浓度成为循环中致动脉粥样硬化脂蛋白数量的直接测量指标。这份关于载脂蛋白 B 作为动脉粥样硬化生物标志物的全球证据综述证实，载脂蛋白 B 是一种单一的致动脉粥样硬化脂质标志物，存在于除高密度脂蛋白胆固醇以外的所有脂质亚组分中，因此，载脂蛋白 B 整合并扩展了甘油三酯和胆固醇的信息，可简化并改善动脉粥样硬化性心血管疾病的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Indian heart journal CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

2.60

自引率

6.70%

发文量

审稿时长

52 days

期刊介绍： Indian Heart Journal (IHJ) is the official peer-reviewed open access journal of Cardiological Society of India and accepts articles for publication from across the globe. The journal aims to promote high quality research and serve as a platform for dissemination of scientific information in cardiology with particular focus on South Asia. The journal aims to publish cutting edge research in the field of clinical as well as non-clinical cardiology - including cardiovascular medicine and surgery. Some of the topics covered are Heart Failure, Coronary Artery Disease, Hypertension, Interventional Cardiology, Cardiac Surgery, Valvular Heart Disease, Pulmonary Hypertension and Infective Endocarditis. IHJ open access invites original research articles, research briefs, perspective, case reports, case vignette, cardiovascular images, cardiovascular graphics, research letters, correspondence, reader forum, and interesting photographs, for publication. IHJ open access also publishes theme-based special issues and abstracts of papers presented at the annual conference of the Cardiological Society of India.